Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma.

BACKGROUND A previous meta-analysis investigated the role of chemotherapy in head and neck locally advanced carcinoma. This work had not been performed on nasopharyngeal carcinoma. OBJECTIVES The aim of the project was to study the effect of adding chemotherapy to radiotherapy on overall survival (OS) and event-free survival (EFS) in patients with nasopharyngeal carcinoma. SEARCH STRATEGY We searched MEDLINE (1966 to October 2003), EMBASE (1980 to October 2003) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 3, 2003) and trial registers. Handsearches of meeting abstracts, references in review articles and of the Chinese medical literature were carried out. Experts and pharmaceutical companies were asked to identify trials. SELECTION CRITERIA Randomised trials comparing chemotherapy plus radiotherapy to radiotherapy alone in locally advanced nasopharyngeal carcinoma were included. DATA COLLECTION AND ANALYSIS The meta-analysis was based on updated individual patient data. The log rank test, stratified by trial, was used for comparisons and the hazard ratios (HR) of death and failure (loco-regional/distant failure or death) were calculated. MAIN RESULTS Eight trials with 1753 patients were included. One trial with a 2 x 2 design was counted twice in the analysis. The analysis was performed including 11 comparisons based on 1975 patients. The median follow up was six years. The pooled hazard ratio of death was 0.82 (95% confidence interval (CI) 0.71 to 0.95; P = 0.006) corresponding to an absolute survival benefit of 6% at five years from chemotherapy (from 56% to 62%). The pooled hazard ratio of tumour failure or death was 0.76 (95% CI 0.67 to 0.86; P < 0.00001) corresponding to an absolute event-free survival benefit of 10% at five years from chemotherapy (from 42% to 52%). A significant interaction was observed between chemotherapy timings and overall survival (P = 0.005), explaining the heterogeneity observed in the treatment effect (P = 0.03) with the highest benefit from concomitant chemotherapy. AUTHORS' CONCLUSIONS Chemotherapy led to a small but significant benefit for overall survival and event-free survival. This benefit was essentially observed when chemotherapy was administered concomitantly with radiotherapy.

[1]  B. O'Sullivan,et al.  Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[2]  Jun Ma,et al.  Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. , 2006, International journal of radiation oncology, biology, physics.

[3]  J. Pignon,et al.  Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. , 2006, International journal of radiation oncology, biology, physics.

[4]  Chong Zhao,et al.  Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. O'Sullivan,et al.  Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Berkhof,et al.  The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases , 2004 .

[9]  J. Sham,et al.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Z. Guan,et al.  Chemotherapy for nasopharyngeal carcinoma , 2004 .

[11]  D. Machin,et al.  Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[14]  T. Mok,et al.  Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Fukuda,et al.  A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma , 2002, Cancer.

[16]  Yue-Cune Chang,et al.  A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. , 2002, International journal of radiation oncology, biology, physics.

[17]  J. Constantinidis,et al.  Kombinierte Radiochemotherapie bei lokal fortgeschrittenem Nasopharynxkarzinom , 2001, HNO.

[18]  J. Pignon,et al.  Meta-analyses of randomised clinical trials in oncology. , 2001, The Lancet. Oncology.

[19]  Jun Ma,et al.  Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Ali,et al.  Chemotherapy in advanced nasopharyngeal cancer. , 2000, Oncology.

[21]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[22]  J P Pignon,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.

[23]  S. Thongprasert,et al.  Preliminary report of the asian‐oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma , 1998, Cancer.

[24]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[26]  Vumca I Trial Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. , 1996, International journal of radiation oncology, biology, physics.

[27]  S. Leung,et al.  A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. , 1995, International journal of radiation oncology, biology, physics.

[28]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[29]  M. Del Vecchio,et al.  Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Fraser,et al.  TREATMENT OF EARLY BREAST CANCER , 1978, The Lancet.

[31]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .